MAFLD Screening in Australia - The Complete Clinical Guide
Australia’s MAFLD burden has moved liver screening out of a niche specialist workflow and into mainstream metabolic care. With around 30% of adults affected, the central challenge is not identifying who is at risk, but how to screen and stage them efficiently at scale.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes. This content does not replace clinician judgement or individual medical advice.
Why MAFLD screening matters now
The market research estimates that more than 6 million Australians are living with MAFLD, with roughly 20% to 30% progressing to MASH. That creates a huge monitoring burden long before patients reach decompensated liver disease.
The new demand is also tied to obesity, type 2 diabetes, and metabolic syndrome, which means the front line is increasingly primary care, endocrine clinics, and community-based specialists rather than only tertiary hepatology services.
Risk factors and who should be screened
High-risk cohorts include people with obesity, type 2 diabetes, hypertension, dyslipidaemia, or other metabolic syndrome features. Many are asymptomatic until disease is already advanced, which is why guideline-led risk stratification matters.
The playbook positions GP practices as key buyers because they already manage the patients most likely to need screening but often lack immediate access to elastography.
The FIB-4 first pathway
Current pathways increasingly begin with simple blood-based scores such as FIB-4. The problem is that a large indeterminate zone still remains, which pushes many patients toward a second-line non-invasive test rather than direct biopsy.
That is where elastography becomes central. A portable, affordable, point-of-care option shortens the distance between risk identification and clinically actionable staging.
Why access is still the Australian bottleneck
The current system concentrates capacity in metropolitan tertiary centres and private specialist clinics. Public wait times can be long, while private access can still mean significant out-of-pocket cost for patients.
The playbook therefore frames Elastography Australia as a way to decentralise liver assessment into community settings and reduce dependence on hospital-based bottlenecks.